ARTICLE | Emerging Company Profile
Catching antibodies with polymers
How Polyneuron’s glycopolymers could treat autoimmune and other diseases
August 8, 2018 6:40 PM UTC
Polyneuron Pharmaceuticals AG's glycopolymers act as decoys for the autoantibodies that drive autoimmune diseases, such as anti-MAG neuropathy, and are designed to be more effective and safer than other therapies.
Polyneuron's Antibody-Catch platform generates glycopolymers that mimic the epitopes found on an autoantibody’s cognate antigen. CSO Pascal Hänggi said the compounds are based on a homoamino acid polymer with carbohydrate groups attached to it and contain a single epitope mimetic that decoys autoantibodies, binding and eliminating them...
BCIQ Company Profiles